A MULTICENTRE STUDY OF CAPECITABINE, OXALIPLATIN PLUS BEVACIZUMAB AS PERIOPERATIVE TREATMENT OF PATIENTS WITH POOR-RISK COLORECTAL LIVERONLY METASTASES NOT SELECTED FOR UPFRONT RESECTION